PENTETATE CALCIUM TRISODIUM
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PENTETATE CALCIUM TRISODIUM (PENTETATE CALCIUM TRISODIUM).
Pentetate calcium trisodium is a chelating agent that forms stable complexes with divalent and trivalent heavy metal ions, such as plutonium, americium, and curium. It enhances the urinary elimination of these metals by increasing the rate of dissociation from tissues and promoting renal excretion.
| Metabolism | Pentetate calcium trisodium is not metabolized; it is excreted unchanged in the urine via glomerular filtration and tubular secretion within 24 hours. |
| Excretion | Primarily renal elimination via glomerular filtration; >90% of absorbed dose excreted unchanged in urine within 24 hours. |
| Half-life | Terminal elimination half-life is approximately 0.6-0.8 hours in patients with normal renal function. |
| Protein binding | Negligible (<5%); primarily binds to plasma metal ions rather than proteins. |
| Volume of Distribution | Approximately 0.2-0.3 L/kg, indicating mainly extracellular distribution with minimal intracellular penetration. |
| Bioavailability | Not applicable; administered exclusively intravenously; oral bioavailability is negligible (<1%) due to poor absorption and gastrointestinal degradation. |
| Onset of Action | Intravenous administration: chelation of metal ions occurs immediately upon distribution; clinical effect on decorporation begins within minutes. |
| Duration of Action | Duration of chelation effect persists for approximately 24 hours; repeat dosing required to maintain decorporation due to rapid renal elimination. |
1 g (one vial) intravenously over 1 hour once daily for up to 5 days.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment recommended; use with caution in severe renal impairment (GFR <30 mL/min) due to potential for accumulation. |
| Liver impairment | No specific dose adjustment provided in labeling; use with caution in severe hepatic impairment. |
| Pediatric use | Children: 14 mg/kg intravenously over 1 hour once daily; maximum 1 g/dose. |
| Geriatric use | No specific dose adjustment; start at lower end of dosing range due to potential for decreased renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PENTETATE CALCIUM TRISODIUM (PENTETATE CALCIUM TRISODIUM).
| Breastfeeding | No human data exist regarding excretion in breast milk. M/P ratio unknown. The manufacturer recommends cautious use due to potential for excretion and adverse effects on nursing infant. Consider alternative therapy if possible. |
| Teratogenic Risk | Pentetate calcium trisodium is a chelating agent used for specific heavy metal poisonings. No controlled human studies exist. Animal studies indicate no directly observed teratogenicity, but caution is warranted. Fetal risk cannot be excluded in any trimester due to potential maternal toxicity and chelation of essential minerals. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to pentetate calcium trisodium or any component of the formulation.
| Precautions | May cause depletion of essential trace metals (e.g., zinc, manganese) with prolonged use; monitor serum zinc levels during therapy. Use with caution in patients with impaired renal function, as drug accumulation may occur. Inhalation of pentetate calcium trisodium aerosol (for pulmonary contamination) may cause bronchospasm. |
Loading safety data…
| Fetal Monitoring | Monitor maternal renal function, serum electrolytes, and complete blood counts. Assure adequate maternal hydration. Assess fetal growth and well-being via ultrasound if ongoing therapy is required. Monitor for signs of trace element deficiency. |
| Fertility Effects | No human studies on fertility. Animal studies have not reported adverse effects on fertility or reproductive performance. Potential disruption of trace element homeostasis may theoretically affect fertility. |